Validation issues frequently seen with initial MAAs
If not, the applicant may use one of the proposed (invented) names or the common name (or scientific name), together with a trademark or the name of the Marketing Authorisation Holder. In both cases, the NRG review is required. Once the NRG review outcome is available, the dossier may be updated as required.
Download Validation issues frequently seen with initial MAAs
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Guidance on Preparation of a Product Registration …
www.asean.orgAn executive summary shall be provided with the common submission dossier template, which shall include the following information:- an overview, e.g., introductory descriptive information on the medical device, the intended uses and indications for use of the medical device,
Home - Food and Drug Administration
www.fda.gov.ph(Common Submission Dossier Template) based on the provisions of AMDD. With the implementation of AO 2018-0002, the FDA through the Center for Device Regulation, Radiation Health and Research (CDRRHR) is also mandated to release list of medical devices per classification based on the classification set forth in the ASEAN AMDD.
Guidance on the format of the risk management plan (RMP) …
www.ema.europa.euthe eCTD dossier of the supporting documents or PSURs , when applicable. Throughout the RMP template, eCTD data/submissions should be read as eCTD or CTD data/submission, corresponding to the type of submission to the competent authority. Specific requirements for different types of initial ... Where the submission of a common, consolidated RMP ...
ASEAN MEDICAL DEVICE DIRECTIVE
asean.orgdevice regulations, common technical documents and the progress made in implementation. HAVE AGREED as follows: ARTICLE 1 GENERAL PROVISIONS (1) Each Member State shall undertake all necessary measures to ensure that only medical devices which conform to the provisions of this ASEAN Agreement on Medical Device Directive (hereinafter referred to as
ASEAN 医療機器指令の概要と各国の 対応状況向調査 - JETRO
www.jetro.go.jpプロセスが一定程度整合されること、統一申請様式(Common Submission Dossier Template、 以下CSDT)を活用した申請が可能となることは、労力・時間・コストを削減する点で大き なメリットとなります。一方、現状では、各国のAMDD へ準拠した法令や許認可プロセス